Synergistic effect of deoxyspergualin (DSP) and cyclosporin A (CsA) in the prevention of spontaneous autoimmune diabetes in BB rats

Clinical and Experimental Immunology

Volumn 105, Issue 2, 1996, Pages 338-343

  Di Marco, R ^a   Zaccone, P ^a   Magro, G ^a   Grasso, S ^a   Lunetta, M ^a   Barcellini, W ^b   Nicolosi, V M ^a   Meroni, P L ^b   Nicoletti, F ^a,c,d  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d NONE   (Italy)

Author keywords

Cyclosporin A; Deoxyspergualin; Diabetes prone BB rat; Immunotherapy; Insulin dependent diabetes mellitus

Indexed keywords

15 DEOXYSPERGUALIN; CYCLOSPORIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG THERAPY; FEMALE; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PREVENTION; PRIORITY JOURNAL; RAT;

EID: 0030037651     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-763.x     Document Type: Article

References (33)

1. Castano L, Eisenbarth GS. Type 1 diabetes: a chronic autoimmune disease of human, mouse and rat. Annu Rev Immunol 1990; 8:647-79.
2. Like AA, Biron CA, Weringer EJ, Byman K, Sroczynski E, Guberski DL. Prevention of diabetes in Biobreeding/Worcester rats with monoclonal antibodies that recognize T lymphocytes or natural killer cells. J Exp Med 1986; 164:1145-9.
3. Shizuru JA, Taylor Edwards C, Banks BA, Gregory AK, Fathman GC. Immunotherapy of the nonobese diabetic mouse. Treatment with an antibody to T-helper lymphocytes. Science (Wash DC) 1988; 240:659-61.
4. + T cells in beta cell destruction. J Autoimmun 1990; 3:101-9.
5. Hutchings PR, O'Reilly L, Parish NM, Waldmann H, Cooke A. The use of a non-depleting anti-CD4 monoclonal antibody to re-establish tolerance to beta cells in NOD mice. Eur J Immunol 1992; 22:1913-8.
6. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994; 91:123-7.
7. Oschilewski U, Kiesel U, Kolb H. Administration of silica prevents diabetes in BB rats. Diabetes 1985; 34:197-9.
8. Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 1994; 15:516-42.
9. Nicoletti F, Di Marco R, Morrone S et al. Reduction of spontaneous autoimmune diabetes in diabetes-prone BB rats with the novel immunosuppressant fucidic acid. Effect on T-cell proliferation and production of IFN-gamma. Immunology 1994; 81:317-21.
10. Nicoletti F, Zaccone P, Di Marco R et al. Effects of sodium fusidate in animal models of insulin-dependent diabetes mellitus and septic shock. Immunology 1995; 85:645-50.
11. Skyler JS, Marks JB. Immune intervention in type 1 diabetes mellitus. Diabetes Rev 1993; 1:15-42.
12. Feutren G, Mihatsch MJ. International kidney biopsy registry of cyclopsorine in autoimmune diseases. Risk factor for in cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 1992; 326:1693.
13. Takeuchi T, Iinuma H, Kunimoto S et al. A new antitumor antibiotic, spergualin: isolation and antitumor activity. J Antibiot 1981; 34:1619-21.
14. Thomson AW. The spectrum of action of new immunosuppressive drugs. Clin Exp Immunol 1992; 89:170-3.
15. Nicoletti F, Meroni PL, Di Marco R et al. The effects of deoxyspergualin on the development of diabetes in diabetes-prone BB rats. Scand J Immunol 1992; 36:415-20.
16. Starndler E, Sandler S. Protection against hyperglycaemia in female nonobese diabetic mice treated with deoxyspergualin. Autoimmunity 1992; 14:159-65.
17. Nicoletti F, Borghi MO, Meroni PL et al. Prevention of cyclophosphamide-induced diabetes in the NOD/Whei mouse with deoxyspergualin. Clin Exp Immunol 1993; 91:232-6.
18. Strandell E, Andersson A, Groth C-G, Sandier S. Effects of (-)15-deoxyspergualin on pancreatic islet B cell function in vitro and on the development of diabetes after multiple low dose streptozotocin administration. Pharmacol Toxicol 1989; 65:114-8.
19. Reichenspurner H, Hildebrant A, Human PA, Boehm DH, Rose AG, Odell JA, Reichart B, Schorlemmer HU. 15-Deoxyspergualin for induction of graft nonreactivity after cardiac and renal allotransplantation in primates. Transplantation 1990; 50:181-5.
20. Nadler SG, Tepper MA, Schacter B, Mazzucco CE. Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp 70 family of heat shock protein. Science 1993; 258:484-6.
21. Hoeger PH, Tepper MA, Faith A, Higgins JA, Lamb JR, Geha RS. Immunosuppressant deoxyspergualin inhibits antigen processing by monocytes. J Immunol 1994; 153:3908-16.
22. Dickneite G, Schorlemmer HU, Sedlacek HH. Decrease of mononuclear phagocyte cell functions and prolongation of graft survival in experimental transplantation by (+)-15-deoxyspergualin. Int J Immunopharmacol 1987; 9:559-64.
23. Waaga AM, Ulrichs K, Krzysmanski M, Treumer J, Hansmann ML, Rommel R, Muller-Ruchholtz W. The immunosuppressive agent 15-deoxyspergualin induces tolerance and modulates MHC antigen expression and interleukin-1 production in the early phase of rat allograft responses. Transplant Proc 1990; 22:1613-4.
24. Nemoto K, Abe F, Nakamura T, Ishikuza M, Takeuchi T, Umezawa H. Blastogenic responses and the release of interleukins 1 and 2 by spleen cells obtained from rat skin allograft recipients administered with 15-deoxyspergualin. J Antibiot Tokio 1987; 40:1062-4.
25. Takasu S, Sakagami K, Morisaki F et al. Immunosuppressive mechanism of 15-deoxyspergualin on sinusoidal lining cells in swine liver transplantation: suppression of MHC class II antigens and interleukin 1 production. J Surg Res 1991; 51:165-71.
26. Kolb H, Kolb-Bachofen V, Roep BO. Autoimmune vs. inflammatory type 1 diabetes: a controversy? Immunol Today 1995; 16:170-172.
27. Bendtzen K. Immune hormones (cytokines); pathogenic role in autoimmune rheumatic diseases and endocrine diseases. Autoimmunity 1989; 2:177-89.
28. Mandrup-Poulsen T, Helqvist S, Molvig J, Wogensen LD, Nerup J. Cytokines as immune effector molecules in endocrine diseases with special reference to insulin-dependent diabetes mellitus. Autoimmunity 1989; 4:191-218.
29. Rabinovitch A. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM: therapeutic intevention by immuno-stimulation? Diabetes 1994; 43:613-21.
30. Formy B, Miller N, Garret R, Peterson CM. Effects of low-dose cyclosporine prophylaxis in nonobese diabetic mice. J Pharm Exp Ther 1987; 241:1106-11.
31. Murase N, Lieberman I, Nalesnik MA et al. Effect of FK 506 on spontaneous diabetes in BB rats. Diabetes 1990; 39:1584-6.
32. Baeder WL, Sredy J, Shegal SN, Chang JY, Adams ML. Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice. Clin Exp Immunol 1992; 89:174-8.
33. Bone AJ, Walker R, Varey AM, Cooke A, Baird JD. Effect of cyclosporin on pancreatic events and development of diabetes in BB/Edinburgh rats. Diabetes 1990; 39:508-14.